RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Chinook Therapeutics Stock

Chinook Therapeutics P/S 2024

Chinook Therapeutics P/S

195.82

Ticker

KDNY

ISIN

US16961L1061

WKN

A2QE43

As of Dec 1, 2024, Chinook Therapeutics's P/S ratio stood at 195.82, a -64.38% change from the 549.71 P/S ratio recorded in the previous year.

The Chinook Therapeutics P/S history

Chinook Therapeutics Aktienanalyse

What does Chinook Therapeutics do?

Chinook Therapeutics Inc. is a biotechnology company focused on the discovery, development, and commercialization of novel therapeutics to treat diseases involving inadequate or faulty kidney function, as well as immune and inflammatory mechanisms. The headquarters of Chinook Therapeutics is located in Seattle, Washington, USA. The company was founded in 2019 by a team of experienced executives in the biotechnology industry, including Tom Frohlich, former Vice President at Omeros Corporation, and Eric Dobmeier and Yi Liu, both formerly with Juno Therapeutics. Chinook Therapeutics aims to improve treatment options for patients with kidney diseases by developing novel therapeutics that influence kidney metabolism and the function of immune and inflammatory mechanisms. Chinook's products are intended to have the potential to slow down or stop the progression of kidney diseases and improve patients' lives. Chinook Therapeutics' business model focuses on supporting the discovery and development of potential therapeutics in the earliest stages to optimize the prospects of later commercialization. The company pursues a pipeline-based strategy that includes a variety of development programs with different focuses. The various divisions of Chinook Therapeutics include the following areas: 1. Therapeutic products for kidney diseases Chinook Therapeutics focuses on the discovery and development of therapeutics for kidney diseases targeting various aspects of kidney metabolism. An example of this is the drug candidate BION-1301, an antibody targeting the binding site of APRIL and BAFF on CD40, with the goal of controlling the progression of glomerulonephritis. 2. Immunology and anti-inflammatory therapeutics Chinook Therapeutics is also specialized in the discovery and development of therapeutics targeting the control of immune and inflammation-related diseases. An example of this is the drug candidate CHN-083, a potent inhibitor of the kinase TRPM8, specifically designed for pain relief in inflammatory conditions. 3. Partnerships with other companies Chinook Therapeutics also collaborates closely with other biotechnology companies and research institutions to accelerate the development of therapeutics and enable the commercialization of innovative products. One such partnership is with Arrowhead Pharmaceuticals, whose RNAi technology Chinook can utilize for developing therapeutics for rare diseases as well as kidney and urinary tract disorders. Chinook Therapeutics has established itself as an innovative biotechnology company driving the development of novel therapeutics in the areas of kidney diseases, immunology, and inflammation. The company relies on a pipeline-based strategy and works closely with other companies and research institutions to efficiently bring its developments to the market. Chinook Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Chinook Therapeutics's P/S Ratio

Chinook Therapeutics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Chinook Therapeutics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Chinook Therapeutics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Chinook Therapeutics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Chinook Therapeutics stock

What is the price-to-earnings ratio of Chinook Therapeutics?

The price-earnings ratio of Chinook Therapeutics is currently 195.82.

How has the price-earnings ratio of Chinook Therapeutics changed compared to last year?

The price-to-earnings ratio of Chinook Therapeutics has increased by -64.38% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Chinook Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Chinook Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Chinook Therapeutics affect the company?

An increase in the price-earnings ratio of Chinook Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Chinook Therapeutics affect the company?

A decrease in the price-earnings ratio of Chinook Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Chinook Therapeutics?

Some factors that influence the price-earnings ratio of Chinook Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Chinook Therapeutics pay?

Over the past 12 months, Chinook Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Chinook Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Chinook Therapeutics?

The current dividend yield of Chinook Therapeutics is .

When does Chinook Therapeutics pay dividends?

Chinook Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Chinook Therapeutics?

Chinook Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Chinook Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Chinook Therapeutics located?

Chinook Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Chinook Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Chinook Therapeutics from 12/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/1/2024.

When did Chinook Therapeutics pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Chinook Therapeutics in the year 2023?

In the year 2023, Chinook Therapeutics distributed 0 USD as dividends.

In which currency does Chinook Therapeutics pay out the dividend?

The dividends of Chinook Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Chinook Therapeutics

Our stock analysis for Chinook Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Chinook Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.